XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Noncontrolling Interest, Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Noncontrolling Interest
Common Stock
Additional paid-in capital
Accumulated other Income (Loss) comprehensive
Accumulated deficit
Series A convertible preferred stock
Series B convertible preferred stock
Series C convertible preferred stock
Balances at Dec. 31, 2019 $ (90,760)     $ 1,208 $ (106) $ (91,862)      
Balance at Beginning of period at Dec. 31, 2019   $ 14,117         $ 21,938 $ 73,029  
Balance at Beginning of period (in shares) at Dec. 31, 2019             2,089,285 2,384,195  
Balance at Beginning of period (in shares) at Dec. 31, 2019     215,890            
Stock-based compensation expense 202     202          
Unrealized loss on foreign currency translation (176)       (176)        
Net loss (9,001)         (9,001)      
Net loss   (205)              
Balances at Mar. 31, 2020 (99,735)     1,410 (282) (100,863)      
Balance at Beginning of period at Mar. 31, 2020   $ 13,912         $ 21,938 $ 73,029  
Balance at end of period (in shares) at Mar. 31, 2020             2,089,285 2,384,195  
Balance at end of period (in shares) at Mar. 31, 2020     215,890            
Balances at Dec. 31, 2020 (117,441)     14,598 (124) (131,915)      
Balance at Beginning of period at Dec. 31, 2020 $ 186,033           $ 30,000 $ 68,995 $ 87,038
Balance at Beginning of period (in shares) at Dec. 31, 2020 12,958,452           2,857,142 2,600,645 7,500,665
Balance at Beginning of period (in shares) at Dec. 31, 2020     337,508            
Conversion of preferred stock to common stock upon closing of the initial public offering $ 186,033   $ 2 186,031          
Temporary equity, conversion of convertible preferred stock into common stock upon closing of the initial public offering (in shares)             (2,857,142) (2,600,645) (7,500,665)
Temporary equity, conversion of convertible preferred stock into common stock upon closing of the initial public offering             $ (30,000) $ (68,995) $ (87,038)
Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)     16,079,230            
Sale of common stock in initial public offering, net of issuance costs 133,023   $ 1 133,022          
Sale of common stock in initial public offering, net of issuance costs (in shares)     8,625,000            
Stock-based compensation expense 1,832     1,832          
Unrealized loss on available-for-sale securities (43)       (43)        
Unrealized loss on foreign currency translation (65)       (65)        
Net loss (13,337)         (13,337)      
Balances at Mar. 31, 2021 $ 190,002   $ 3 $ 335,483 $ (232) $ (145,252)      
Balance at end of period (in shares) at Mar. 31, 2021 0                
Balance at end of period (in shares) at Mar. 31, 2021     25,041,738